Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 01: 38 - 40

DOI: https://doi.org/10.16139/j.1007-9610.2021.01.008

Experts forum

Intraperitoneal combined with systemic neoadjuvant chemotherapy for treatment of peritoneal metastatic gastric cancer: clinical significance and key

Expand

Received date: 2021-01-13

  Online published: 2022-07-28

Fold

Cite this article

YAN Chao, YAN Min, ZHU Zhenggang . Intraperitoneal combined with systemic neoadjuvant chemotherapy for treatment of peritoneal metastatic gastric cancer: clinical significance and key[J]. Journal of Surgery Concepts & Practice, 2021 , 26(01) : 38 -40 . DOI: 10.16139/j.1007-9610.2021.01.008

References

[1] Yamaguchi T, Takashima A, Nagashima K, et al. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology(CY1) or localized peritoneal metastasis(P1a): a multi institutional retrospective study[J]. Gastric Cancer,2020-11-11.doi: 10.1007/s10120-020-01137-6.Epub ahead of print.PMID: 33179192.
[2] Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3):309-318.
[3] Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
[4] Gong Y, Wang P, Zhu Z, et al. Benefits of surgery after neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal metastasis: a meta-analysis[J]. J Surg Res, 2020, 245:234-243.
[5] 严超, 石红鹏, 刘瑩, 等. 胃癌腹膜转移的新辅助腹腔内联合全身化疗:初步研究[J]. 外科理论与实践, 2017, 22(1):32-39.
[6] Li C, Yan M, Chen J, et al. Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination[J]. J Surg Oncol, 2010, 102(5):361-365.
[7] 严超, 杨中印, 施敏, 等. 胃癌术后腹膜复发转移的腹腔镜诊断和腹腔内联合全身双向化疗的临床疗效[J]. 中华胃肠外科杂志, 2020, 23(5):492-498.
[8] Yang Z, Yan C, Yu Z, et al. Downregulation of CDH11 promotes metastasis and resistance to paclitaxel in gastric cancer cells[J]. J Cancer, 2021, 12(1):65-75.
[9] Yang Z, Li C, Liu W, et al. Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis[J]. Chin J Cancer Res, 2020, 32(4):497-507.
[10] Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Jpn J Clin Oncol, 2012, 42(11):1013-1019.
Options
Outlines

/

〈 〉